ranibizumab

Real-world outcomes with aflibercept better in treatment-naïve patientsAfter 12 months of treatment with intravitreal aflibercept injections, both treatment-naïve and pre-treated patients demonstrated visual acuity gains. Visual acuity improvement was higher in treatment-naïve patients.
Aflibercept rivals laser for diabetic retinopathyIntravitreal aflibercept worked better than panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) in a new head-to-head trial, according to researchers.
Ranibizumab proves effective for DMO in NHS clinicsPatients treated for diabetic macular oedema with ranibizumab in the UK National Health Service (NHS) are getting benefits similar to those seen in clinical trials, according to a new study
Latest concepts in steroid therapy for diabetic macular oedemaSteroids are an important second-line treatment for the treatment of diabetic macular oedema. While side effects remain a concern, modern formulations of intravitreal steroid allow the treatment to be tailored to the individual patient.
The AAO's preferred practice patterns for AMDHigh-level evidence supports the use of anti-vascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (AMD), but falls short of recommending any one agent over another in terms of efficacy or safety, said Paul Sternberg Jr., MD.
Anti-VEGF drugs: Safe and effective for treating DMEData from large randomized trials indicate that diabetic macular edema can be treated safely and effectively with anti-vascular endothelial growth factor therapies.
Aflibercept effects mild in patients not responding to ranibizumabSwitching from ranibizumab to aflibercept may allow some patients to extend the time between treatments for neovascular age-related macular degeneration (AMD), researchers say.
Combination anti-VEGF, navigated laser for DME on a par with monotherapyData show that the combination of navigated laser and anti-vascular endothelial growth factor (VEGF) compares favorably with anti-VEGF monotherapy.
Topical drug improves anti-VEGF effectiveness for retinal vein occlusionNew Ohr Pharmaceuticals formulation of topical squalamine was found to improve anti-VEGF effectiveness for the treatment of retinal vein occlusion.
Ranibizumab proves instrumental for DME patients in RIDE, RISE trialsRanibizumab provided improvements in visual acuity and DR that were stable over the long term when the drug was administered on an as-needed regimen to patients with diabetic macular edema in the RIDE and RISE trials.